Washington Drug Letter
Aug. 13, 2012
| Vol.
44 No.
32
SEC Probes Teva Over Possible FCPA Violations in Latin America
Teva Pharmaceuticals is the target of an SEC bribery investigation and has been handed a subpoena for documents related to its compliance with the Foreign Corrupt Practice Act (FCPA) in Latin America.
This article is viewable by subscribers only. To view this article, please select an option below.
|